Does Lacosamide Interact with Common Medications?
Lacosamide, an antiepileptic drug sold as Vimpat, has moderate interactions with drugs that induce or inhibit CYP enzymes, particularly CYP2C19 and CYP3A4. Strong CYP3A4 inducers like carbamazepine, phenytoin, and phenobarbital lower lacosamide exposure by 20-40%, potentially reducing seizure control.1 Rifampin has a similar effect. Conversely, strong CYP2C19 inhibitors like omeprazole can increase lacosamide levels by up to 20%, raising toxicity risk.[1]
How Does Lacosamide Interact with Other Antiepileptics?
Co-administration with enzyme-inducing antiepileptics (e.g., carbamazepine, phenytoin, oxcarbazepine) decreases lacosamide AUC by 15-30%, often requiring dose adjustments upward.1 Valproate slightly increases lacosamide exposure (10-15%), while levetiracetam and lamotrigine show no significant interaction. Dual therapy with lacosamide and another sodium channel blocker like lamotrigine or carbamazepine may amplify CNS depression or cardiac effects like PR interval prolongation.2
What About Interactions with Central Nervous System Depressants?
Lacosamide enhances effects of alcohol, opioids, benzodiazepines, and barbiturates, increasing dizziness, somnolence, and ataxia. Avoid or limit alcohol, as it worsens cognitive impairment.1 Combining with other sedatives heightens fall risk, especially in elderly patients.
Cardiac Risks and Interactions
Lacosamide causes dose-dependent PR interval prolongation, raising atrioventricular block risk when combined with beta-blockers, calcium channel blockers (e.g., verapamil, diltiazem), or digoxin. Monitor ECG in patients on these drugs; avoid in those with conduction disorders.1 No major QT prolongation interactions noted.
Interactions with Hormonal Contraceptives or Other Drugs?
Lacosamide does not affect hormonal contraceptive efficacy, unlike some enzyme-inducing antiepileptics.[1] It has minimal interactions with warfarin, metformin, or statins. Omeprazole and other proton pump inhibitors slightly elevate lacosamide levels via CYP2C19 inhibition.2
Management and Monitoring Tips
Adjust lacosamide dose by 25-50% when starting strong inducers; taper carefully when discontinuing. Therapeutic drug monitoring is not routine but useful in polytherapy. Report symptoms like dizziness or bradycardia promptly.1
[1]: Drugs.com - Lacosamide Interactions